Prevalence and complementary distribution of FGFR3 alterations and ERBB2 amplification in metastatic urothelial carcinoma: a nationwide registry analysis.
Two genetic mutations almost never occur together in bladder cancer, allowing doctors to sequence targeted drugs more strategically.
Nationwide Japanese registry reveals FGFR3 alterations and ERBB2 amplification show near-mutually exclusive distribution in metastatic urothelial carcinoma, informing sequencing of erdafitinib vs. trastuzumab deruxtecan-based targeted therapies and supporting routine molecular profiling in this indication.
What the study was
- Study design
- retrospective_cohort
- Category
- precision_oncology
- Maturity
- clinical
- Journal
- International Journal of Clinical Oncology
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.